{"disease":{"id":"myeloproliferative-syndrome","name":"myeloproliferative syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT05564390","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00074490","title":"Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":442,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00003816","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02158858","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":336,"lead_sponsor_name":"Constellation Pharmaceuticals","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03887156","title":"Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":227,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02861417","title":"Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00003838","title":"Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":true},{"nct_id":"NCT01572662","title":"Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03852407","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":114,"lead_sponsor_name":"University of Liege","has_results":false},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00003687","title":"Treatment for Chronic Pain in Patients With Advanced Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"NCIC Clinical Trials Group","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT01822509","title":"Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00448201","title":"Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT01660607","title":"Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04493138","title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03630991","title":"Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01366612","title":"Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"Hackensack Meridian Health","has_results":true},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06597734","title":"A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04992949","title":"Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"French Innovative Leukemia Organisation","has_results":false},{"nct_id":"NCT00053989","title":"NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05825326","title":"Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Sociedad de Lucha Contra el Cáncer del Ecuador","has_results":false},{"nct_id":"NCT01384513","title":"A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT03128359","title":"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT00281814","title":"Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03907436","title":"The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT04631211","title":"Thrombosomes® in Bleeding Thrombocytopenic Patients Study","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Cellphire Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02890758","title":"Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Brenda Cooper, MD","has_results":false},{"nct_id":"NCT02129582","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT05400122","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":12,"lead_sponsor_name":"David Wald","has_results":false},{"nct_id":"NCT02960646","title":"Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02666950","title":"WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04250051","title":"Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03807063","title":"Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false}],"total":44},"guidelines":[],"source":"Drug Landscape verified database"}